email article
Among patients with moderate to severe COVID-19, there was no difference in length of hospital stay in those given a single 200,000-IU dose of vitamin D
3 versus those given placebo in a randomized trial in Brazil.
Median length of hospital stay was about 7 days for both groups, with no significant differences in secondary outcomes including in-hospital mortality, admission to ICU, or need for mechanical ventilation, reported Rosa Pereira, MD, PhD, of Universidade de Sao Paulo, and colleagues in an online edition of
An accompanying editorial by David Leaf, MD, of Brigham and Women s Hospital in Boston, and Adit Ginde, MD, MPH, of University of Colorado School of Medicine in Aurora, noted that prior research showed that lower levels of vitamin D were independently associated with worse outcomes in patients with acute illness, but also that vitamin D supplementation as a treatment had no impact on clinical outcomes.
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.
Lung ultrasound, considered a simple method for diagnosing lung disease, can also help predict the clinical progression of severe Covid-19 patients, a new study suggests.The study, published in the journal Annals of Intensive Care, showed that .
Herd immunity inference from Delhi s serosurvey to be taken with pinch of salt, say scientists
Latest sero survey shows 56.13 per cent of people in the Delhi have antibodies against Covid but scientists are wary.
Share Via Email
| A+A A-
A woman wearing a protective mask to help curb the spread of the coronavirus walks in front of social distancing notice. (Photo | AP) By PTI
NEW DELHI: Has Delhi achieved herd immunity against COVID-19? It is tempting to say yes given the dipping case count assessed in tandem with the latest sero survey that shows 56.13 per cent of people in the city have antibodies against the infection but scientists are wary.
Has Delhi achieved herd immunity against COVID-19? It is tempting to say yes given the dipping case count assessed in tandem with the latest sero survey that shows 56.13 per cent of people in the city have antibodies against the infection but scientists are wary. On Tuesday, the Delhi government announced the results of the fifth sero survey, with a sample of 28,000 across 11 districts in Delhi. The score of 56.13 per cent seroprevalence with Southwest Delhi highest at 62.18 per cent and North Delhi lowest at 49.09 per cent indicates perhaps that the national capital could be the first in the country to achieve herd immunity.